Literature DB >> 20933243

Can lung cancer screening by computed tomography be effective in areas with endemic histoplasmosis?

Sandra L Starnes1, Michael F Reed, Cris A Meyer, Ralph T Shipley, Abdul-Rahman Jazieh, Elsira M Pina, Kevin Redmond, Lynn C Huffman, Prakash K Pandalai, John A Howington.   

Abstract

OBJECTIVE: Low-dose chest computed tomography (CT) is being evaluated in several national trials as a screening modality for the early detection of lung cancer. The goal of the present study was to determine whether lung cancer screening could be done while minimizing the number of benign biopsy specimens taken in an area endemic for histoplasmosis.
METHODS: The subjects were recruited by letters mailed to area physicians and local advertisement. The inclusion criteria were age older than 50 years and at least a 20 pack-year smoking history. The exclusion criteria were symptoms suggestive of lung cancer or a history of malignancy in the previous 5 years. The participants completed a questionnaire and underwent a chest CT scan at baseline and annually for 5 years. The management of positive screening results was determined using a defined algorithm: annual follow-up CT scan for nodules less than 5 mm; 6-month follow-up CT scan for nodules 5 to 7 mm; review by our multidisciplinary tumor board for nodules 8 to 12 mm; and biopsy for nodules greater than 12 mm.
RESULTS: A total of 132 patients were recruited. Of the 132 patients, 61% had positive baseline CT findings and 22% had positive findings on the annual CT scans. Six cancers were detected. Of these 6 patients, 5 had stage I disease and underwent lobectomy, and 1 had stage IIIA disease and underwent induction chemotherapy and radiotherapy followed by lobectomy. All patients were alive and disease free at a mean follow-up of 41.7 ± 18.6 months. No biopsies were performed for benign lesions. Also, no cancers were missed when the protocol was followed.
CONCLUSIONS: Screening with CT can be done effectively in an area endemic for histoplasmosis while minimizing benign biopsies. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20933243     DOI: 10.1016/j.jtcvs.2010.08.045

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  13 in total

Review 1.  Small pulmonary nodules in baseline and incidence screening rounds of low-dose CT lung cancer screening.

Authors:  Joan E Walter; Marjolein A Heuvelmans; Matthijs Oudkerk
Journal:  Transl Lung Cancer Res       Date:  2017-02

2.  Predicting lung cancer prior to surgical resection in patients with lung nodules.

Authors:  Stephen A Deppen; Jeffrey D Blume; Melinda C Aldrich; Sarah A Fletcher; Pierre P Massion; Ronald C Walker; Heidi C Chen; Theodore Speroff; Catherine A Degesys; Rhonda Pinkerman; Eric S Lambright; Jonathan C Nesbitt; Joe B Putnam; Eric L Grogan
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

3.  Histoplasmosis mimicking primary lung neoplasm.

Authors:  Minesh Kooblall; Barry Keane; Grainne Murray; Eddie Moloney
Journal:  BMJ Case Rep       Date:  2014-04-11

4.  Accuracy of a Novel Histoplasmosis Enzyme Immunoassay to Evaluate Suspicious Lung Nodules.

Authors:  Stephen A Deppen; Pierre P Massion; Jeffrey Blume; Ronald C Walker; Sanja Antic; Heidi Chen; Michele M Durkin; L Joseph Wheat; Eric L Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-19       Impact factor: 4.254

5.  Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules.

Authors:  Mingzhi Ye; Shiyong Li; Weizhe Huang; Chunli Wang; Liping Liu; Jun Liu; Jilong Liu; Hui Pan; Qiuhua Deng; Hailing Tang; Long Jiang; Weizhe Huang; Xi Chen; Di Shao; Zhiyu Peng; Renhua Wu; Jing Zhong; Zhe Wang; Xiaoping Zhang; Karsten Kristiansen; Jian Wang; Ye Yin; Mao Mao; Jianxing He; Wenhua Liang
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

6.  Validation of Histoplasmosis Enzyme Immunoassay to Evaluate Suspicious Lung Nodules.

Authors:  Maren E Shipe; Stephen A Deppen; Shelbi Sullivan; Michael Kammer; Sandra L Starnes; David O Wilson; Pierre P Massion; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2020-07-16       Impact factor: 4.330

7.  Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.

Authors:  Elena Kupert; Marshall Anderson; Yin Liu; Paul Succop; Linda Levin; Jiang Wang; Kathryn Wikenheiser-brokamp; Pingping Chen; Susan M Pinney; Trudy Macdonald; Zhongyun Dong; Sandra Starnes; Shan Lu
Journal:  BMC Cancer       Date:  2011-12-09       Impact factor: 4.430

8.  Modeling the Impact of Delaying the Diagnosis of Non-Small Cell Lung Cancer During COVID-19.

Authors:  Maren E Shipe; Diane N Haddad; Stephen A Deppen; Benjamin D Kozower; Eric L Grogan
Journal:  Ann Thorac Surg       Date:  2020-10-19       Impact factor: 4.330

9.  Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.

Authors:  Zhongyun Dong; Jaroslaw Meller; Paul Succop; Jiang Wang; Kathryn Wikenheiser-Brokamp; Sandra Starnes; Shan Lu
Journal:  Int J Oncol       Date:  2014-06-10       Impact factor: 5.650

Review 10.  Chronic Pulmonary Histoplasmosis-A Scoping Literature Review.

Authors:  Jacob Baker; Chris Kosmidis; Anna Rozaliyani; Retno Wahyuningsih; David W Denning
Journal:  Open Forum Infect Dis       Date:  2020-04-06       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.